Back to Directory

Kelly Colsh

Email

kelly.colsh@nih.gov

Phone

240-669-5721

Institution

NIH, NIAID, DAIDS, PAB

Title

Pharmacist

Address

DAIDS Pharmaceutical Affairs Branch
5601 Fishers Lane
Room 9E15
Rockville, MD 20852
USA

Request an Update

Affiliated Studies

IMPAACT 2042: Tatelo Plus

DAIDS Number

Research Area

Cure and Immunotherapy

Study Status

IMPAACT 2009 : Pharmacokinetics, Feasibility, Acceptability, and Safety of Oral Pre-Exposure Prophylaxis for Primary HIV Prevention during Pregnancy and Postpartum in Adolescents and Young Women and their Infants

DAIDS Number

Research Area

Study Status

Closed to Follow Up

IMPAACT 2021: Randomized Phase I/II Study of the Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV delta NS2/ delta 1313/I1314L, RSV 6120/ delta NS2/1030s, RSV 276 or Placebo, Delivered as Nose Drops to RSV-Seronegative Children 6 to 24 Months of Age

DAIDS Number

Research Area

Cure and Immunotherapy

Study Status

Participants Off Study and Primary Analysis Completed

IMPAACT 2018: Randomized Phase I Study of the Infectivity, Safety, and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV delta NS2/delta 1313/I1314L or RSV 276 or Placebo, Delivered as Nose Drops to RSV-Seronegative Infants 6 to 24 Months of Age

DAIDS Number

Research Area

Complications & Comorbidities

Study Status

Show All